Thermo Fisher Scientific market cap TMO
Share price times shares outstanding: what the whole company sells for, since 2009.
- Today, Oct 23, 2026
- $249.1B
- Highest close in our data
- $262.9B
- Dec 2021
Thermo Fisher Scientific is worth $249.1B at the close on Oct 23, 2026, at $673.82 a share.
That is up 15% over the last year and up 0% over five years.
Its highest close in our data was $262.9B in Dec 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $249.1B | $162.9B | $255.1B | +14% |
| 2025 | $218.2B | $148.6B | $228.6B | +8% |
| 2024 | $201.2B | $196.3B | $235.2B | −2% |
| 2023 | $205.1B | $166.5B | $232.8B | −5% |
| 2022 | $216B | $194.4B | $239.2B | −18% |
| 2021 | $262.9B | $175.2B | $262.9B | +42% |
| 2020 | $184.6B | $109.4B | $209.1B | +41% |
| 2019 | $130.9B | $89.3B | $131B | +46% |
| 2018 | $89.6B | $80.3B | $100.5B | +18% |
| 2017 | $76.1B | $56.7B | $77.7B | +37% |
| 2016 | $55.7B | $49.2B | $62.7B | −2% |
| 2015 | $56.6B | $48.3B | $56.6B | +11% |
| 2014 | $51.1B | $39.7B | $51.7B | +28% |
| 2013 | $40B | $23.5B | $40B | +76% |
| 2012 | $22.7B | $18B | $23.2B | +33% |
| 2011 | $17B | $16.6B | $25B | −23% |
| 2010 | $22B | $17.6B | $22.6B | +13% |
| 2009 | $19.5B | $18B | $19.9B | n/a |
Against its peers
Companies in Medical - Diagnostics & Research nearest Thermo Fisher Scientific's size, closest first, today.
| Company | Market cap |
|---|---|
| TMOThermo Fisher Scientific | $249.1B |
| DHRDanaher | $162B |
| AAgilent Technologies | $48.8B |
| IQVIQVIA | $46B |
| WATWaters | $44.6B |
| IDXXIDEXX Laboratories | $44.1B |
| ILMNIllumina | $40.7B |
| MTDMettler-Toledo International | $33.5B |
| DGXQuest Diagnostics | $26.7B |
| LHLabcorp | $26.7B |
| Peer median | $44.1B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Thermo Fisher Scientific
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.